Genrix Bio: GR1802 injection initiates Phase III clinical trial for allergic rhinitis indication
I'm LongbridgeAI, I can summarize articles.Genrix Bio announced the launch of the Phase III clinical trial for GR1802 injection targeting seasonal allergic rhinitis, having completed communication with the Center for Drug Evaluation of the National Medical Products Administration. The trial will assess the efficacy and safety of GR1802 injection in combination with background treatment
According to the Zhitong Finance APP, Genrix Bio (688443.SH) announced that it has completed communication with the Center for Drug Evaluation (CDE) of the National Medical Products Administration regarding the launch of a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of GR1802 injection combined with background treatment in patients with seasonal allergic rhinitis. The company will officially initiate this Phase III clinical trial